The treatment, called EOS-448, is in a phase 1 study involving patients with advanced solid tumours. GlaxoSmithKline and iTeos plan to begin testing the treatment’s administration with dostarlimab, another cancer antibody, in 2022.
GlaxoSmithKline will pay iTeos $625 million upfront, as well as up to $1.45 billion in potential milestones payments.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
